Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 1, 2009, Pages 135-140

  Sofuoglu, Mehmet ^a   Waters, Andrew J ^b   Mooney, Marc ^c   O'Malley, Stephanie S ^a  

^a YALE UNIVERSITY   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Intravenous nicotine; Minocycline; Nicotine dependence; Nitric oxide; Nitric oxide synthase

Indexed keywords

MINOCYCLINE; NICOTINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBO;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; DRUG USE; FEMALE; HUMAN; MALE; PHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADULT; AFFECT; ANTI-INFECTIVE AGENTS; ATTENTION; COTININE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MINOCYCLINE; NICOTINE; NICOTINIC AGONISTS; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; SMOKING; SUBSTANCE WITHDRAWAL SYNDROME;

RODENTIA;

EID: 58549104107     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.11.004     Document Type: Article

References (41)

1. Allen J.C. Minocycline. Ann Intern Med 85 (1976) 482-487
2. Bisaga A., Padilla M., Garawi F., Sullivan M.A., and Haney M. Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory. Hum Psychopharmacol 22 (2007) 41-47
3. Buchhalter A.R., Acosta M.C., Evans S.E., Breland A.B., and Eissenberg T. Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction 100 (2005) 550-559
4. Cahill K., Stead L.F., and Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev (2007) CD006103
5. Cappelleri J.C., Bushmakin A.G., Baker C.L., Merikle E., Olufade A.O., and Gilbert D.G. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 32 (2007) 912-923
6. Carter B.L., Lam C.Y., Robinson J.D., Paris M.M., Waters A.J., Wetter D.W., and Cinciripini P.M. Real-time craving and mood assessments before and after smoking. Nicotine Tob Res. 10 7 (2008) 1165-1169 Jul
7. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98 (2001) 14669-14674
8. Erdal E.P., Litzinger E.A., Seo J., Zhu Y., Ji H., and Silverman R.B. Selective neuronal nitric oxide synthase inhibitors. Curr Top Med Chem 5 (2005) 603-624
9. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. In: Service, USDoHaHSPH, (Ed)., Rockville, MD, 2008.
10. Harvey D.M., Yasar S., Heishman S.J., Panlilio L.V., Henningfield J.E., and Goldberg S.R. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) 175 (2004) 134-142
11. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 (1991) 1119-1127
12. Hoffmann D., and Wynder E.L. Chemical constituents and bioactivity of tobacco smoke. IARC Sci Publ (1986) 145-165
13. Hughes J.R., and Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43 (1986) 289-294
14. Hughes J.R., and Hatsukami D.K. Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight. J Subst Abuse 9 (1997) 151-159
15. Jonas M., and Cunha B.A. Minocycline. Ther Drug Monit 4 (1982) 137-145
16. Kenford S.L., Smith S.S., Wetter D.W., Jorenby D.E., Fiore M.C., and Baker T.B. Predicting relapse back to smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol 70 (2002) 216-227
17. Kim S.S., Kong P.J., Kim B.S., Sheen D.H., Nam S.Y., and Chun W. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 27 (2004) 314-318
18. Lampl Y., Boaz M., Gilad R., Lorberboym M., Dabby R., Rapoport A., et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69 (2007) 1404-1410
19. Macdonald H., Kelly R.G., Allen E.S., Noble J.F., and Kanegis L.A. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 14 (1973) 852-861
20. Malin D.H., Lake J.R., Shenoi M., Upchurch T.P., Johnson S.C., Schweinle W.E., et al. The nitric oxide synthesis inhibitor nitro-l-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 140 (1998) 371-377
21. Martin J.L., and Itzhak Y. 7-Nitroindazole blocks nicotine-induced conditioned place preference but not LiCl-induced conditioned place aversion. Neuroreport 11 (2000) 947-949
22. McNair D., Lorr M., and Dropperman L. Profile of Mood States: Bipolar Form. Educational and Industrial Testing Service, Educational and Industrial Testing Service (1988)
23. Pae C.U., Marks D.M., Han C., and Patkar A.A. Does minocycline have antidepressant effect?. Biomed Pharmacother 62 (2008) 308-311
24. Robertson I.H., Manly T., Andrade J., Baddeley B.T., and Yiend J. 'Oops!': performance correlates of everyday attentional failures in traumatic brain injured and normal subjects. Neuropsychologia 35 (1997) 747-758
25. Sadowski T., and Steinmeyer J. Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol 28 (2001) 336-340
26. Sahraei H., Falahi M., Zarrindast M.R., Sabetkasaei M., Ghoshooni H., and Khalili M. The effects of nitric oxide on the acquisition and expression of nicotine-induced conditioned place preference in mice. Eur J Pharmacol 503 (2004) 81-87
27. SAS Institute Inc. The SAS System for Windows (2007), SAS Institute Inc., Cary, NC
28. Schilstrom B., Mameli-Engvall M., Rawal N., Grillner P., Jardemark K., and Svensson T.H. Nitric oxide is involved in nicotine-induced burst firing of rat ventral tegmental area dopamine neurons. Neuroscience 125 (2004) 957-964
29. Sofuoglu M., Babb D., and Hatsukami D.K. Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine Tob Res 5 (2003) 947-953
30. Sofuoglu M., Mouratidis M., Yoo S., Culligan K., and Kosten T. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 181 (2005) 504-510
31. Sofuoglu M., Poling J., Mouratidis M., and Kosten T. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 184 (2006) 645-651
32. Sofuoglu M., Waters A.J., Mooney M., and Kosten T. Riluzole and d-amphetamine interactions in humans. Prog Neuro-psychopharmacol Biol Psychiatry 32 (2008) 16-22
33. Sofuoglu M., Yoo S., Hill K.P., and Mooney M. Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology 33 (2008) 715-720
34. Stead L.F., Perera R., Bullen C., Mant D., and Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (2008) CD000146
35. Stirling D.P., Koochesfahani K.M., Steeves J.D., and Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 11 (2005) 308-322
36. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 (2006) 664-671
37. Thomas M., Ashizawa T., and Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord 19 (2004) 692-695
38. Tidey J.W., O'Neill S.C., and Higgins S.T. d-Amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology (Berl) 153 (2000) 85-92
39. Vleeming W., Rambali B., and Opperhuizen A. The role of nitric oxide in cigarette smoking and nicotine addiction. Nicotine Tob Res 4 (2002) 341-348
40. Watson D., Clark L.A., and Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54 (1988) 1063-1070
41. Westman E.C., Levin E.D., and Rose J.E. Smoking while wearing the nicotine patch: is smoking satisfying or harmful?. Clin Res 40 (1992) 871A